K. Ishimoto
- Neurology top 10%
- Neuroblastoma Research and Treatments 5
- Hematology top 10%
-
- Immunotherapy and Immune Responses 4
-
- Blood disorders and treatments 3
-
- Acute Lymphoblastic Leukemia research 4
-
- Histiocytic Disorders and Treatments 2
-
- Cancer therapeutics and mechanisms 2
-
- Neuroendocrine Tumor Research Advances 2
-
- Parvovirus B19 Infection Studies 2
- Co-authors
- Nobutaka KiyokawaT KanohJunichi HataY NiwaHirohiko AkamatsuYoichi HachitandaHiroyuki ShimadaJunichiro Fujimoto
- Cited by
- NeurologyHematologyImmunology
- Journals
- European Journal of Pediatrics (3 papers)Journal of Pediatric Surgery (2 papers)Drugs (2 papers)
- Partner nations
- JapanUnited States
In The Last Decade
K. Ishimoto
30 papers receiving 503 citations
Peers
Comparison fields: 5 of 79
- Neurology 107
- Hematology 71
- Immunology 115
- Oncology 97
- Genetics 36
Countries citing papers authored by K. Ishimoto
This map shows the geographic impact of K. Ishimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Ishimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Ishimoto more than expected).
Fields of papers citing papers by K. Ishimoto
This network shows the impact of papers produced by K. Ishimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Ishimoto. The network helps show where K. Ishimoto may publish in the future.
Co-authorship network
The 25 scholars most cited alongside K. Ishimoto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2006 | 23 | |
| 3 | 2002 | 41 | |
| 4 | 1999 | 23 | |
| 5 | 1998 | 18 | |
| 6 | 1998 | 1 | |
| 7 | 1995 | 4 | |
| 8 | 1995 | 8 | |
| 9 | 1993 | 35 | |
| 10 | 1993 | 11 | |
| 11 | 1993 | 9 | |
| 12 | 1992 | 27 | |
| 13 | 1992 | 19 | |
| 14 | 1991 | 24 | |
| 15 | Biological analysis of neuroblastoma in mass screened negative cases. | 1991 | 6 |
| 16 | 1990 | 34 | |
| 17 | 1988 | 23 | |
| 18 | 1987 | 5 | |
| 19 | 1987 | 17 | |
| 20 | 1985 | 2 |
About K. Ishimoto
K. Ishimoto is a scholar working on Neurology, Oncology and Immunology, having authored 31 papers that have together received 525 indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (5 papers), Immunotherapy and Immune Responses (4 papers), Acute Lymphoblastic Leukemia research (4 papers), Blood disorders and treatments (3 papers), Histiocytic Disorders and Treatments (2 papers), Cancer therapeutics and mechanisms (2 papers), Neuroendocrine Tumor Research Advances (2 papers) and Parvovirus B19 Infection Studies (2 papers). The work is most often cited by research in Neurology (107 citations), Hematology (71 citations) and Immunology (115 citations). K. Ishimoto has collaborated with scholars based in Japan and United States. Frequent co-authors include Nobutaka Kiyokawa, T Kanoh, Junichi Hata, Y Niwa, Hirohiko Akamatsu, Yoichi Hachitanda, Hiroyuki Shimada, Junichiro Fujimoto, Hiroo Fujita and Takeshi Miyano. Their work appears in journals such as European Journal of Pediatrics, Journal of Pediatric Surgery, Drugs, Gastroenterology and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.